Skip to main content

Table 1 Correlations between ATR expression and clinicopathological characteristics in breast cancer patients

From: Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients

ParameterTotal (n = 103) (%)ATR in stromal fibroblastsPvalue
HighIntermediateLow
Stage
 T230 (29.13)6 (5.83)17 (16.50)7 (6.80) 
 T329 (28.16)10 (9.71)13 (12.62)6 (5.83)0.3308
 T443 (41.75)14 (13.59)14 (13.59)15 (14.56) 
 Tx1 (0.97)0 (0.00)1 (0.97)0 (0.00) 
KI-67 index
 085 (84.16)26 (24.75)37 (36.63)23 (22.77) 
 ≤ 152 (1.98)0 (0.00)2 (1.98)0 (0.00)0.7652
 >1514 (13.86)5 (4.95)5 (4.95)4 (3.96) 
HIS subtype
 None invasive1 (0.97)1 (0.97)0 (0.00)0 (0.00) 
 Invasive ductal Ca85 (82.52)23 (22.33)40 (38.83)22 (21.36) 
 1,43 (2.91)1 (0.97)1 (0.97)1 (0.97)0.5887
 Invasive ductal Ca with DCIS11 (10.68)3 (2.91)4 (3.88)4 (3.88) 
 Infiltrating lobular Ca1 (0.97)0 (0.00)0 (0.00)1 (0.97) 
 3, 41 (0.97)1 (0.97)0 (0.00)0 (0.00) 
 Other1 (0.97)1 (0.97)0 (0.00)0 (0.00) 
Recurrence
 No63 (61.76)18 (17.65)35 (34.31)10 (9.80)0.0017
 Yes39 (38.24)11 (10.78)10 (9.80)18 (17.65) 
Grade
 G13 (2.91)1 (0.97)1 (0.97)1 (0.97) 
 G246 (44.66)9 (8.74)27 (26.21)10 (9.71)0.0473
 G354 (52.43)20 (19.42)17 (16.50)17 (16.50) 
Progression
No73 (72.28)13 (12.87)40 (39.60)20 (19.81)0.0003
Yes28 (27.72)14 (13.86)4 (3.96)18 (9.9) 
Survival status
 Alive84 (81.55)24 (23.30)45 (43.69)15 (14.56)< 0.0001
 Dead19 (18.45)6 (5.83)0 (0.00)13 (12.62) 
Duration of clinical follow-up (years, mean ± SD) 4.165000005.007555563.874642860.0390
ParameterTotal (n = 103) (%)ATR in cancer cellsPvalue
HighIntermediateLow
Tumor size
 ≤ 535 (40.23)7 (8.05)15 (17.24)13 (14.94)0.4008
 >552 (59.77)8 (9.20)17 (19.54)27 (31.03) 
Stage
 T230 (29.13)6 (5.83)12 (11.65)12 (11.65) 
 T329 (28.16)6 (5.83)10 (9.71)13 (12.62)0.6772
 T443 (41.75)6 (5.83)16 (15.53)21 (20.39) 
 Tx1 (0.97)1 (0.97)0 (0.00)0 (0.00) 
KI-67 index
 085 (84.16)13 (12.87)32 (31.68)40 (39.60)0.1525
 ≤ 152 (1.98)0 (0.00)1 (0.99)1 (0.99) 
 >1514 (13.86)6 (5.94)3 (2.97)5 (4.95) 
HIS subtype
 None invasive1 (0.97)0 (0.00)1 (0.97)0 (0.00) 
 Invasive ductal Ca85 (82.52)13 (12.62)33 (32.04)39 (37.86) 
 1,43 (2.91)0 (0.00)1 (0.97)2 (1.94)0.1336
 Invasive ductal Ca with DCIS11 (10.68)4 3.88)2 (1.94)5 (4.85) 
 Infiltrating lobular Ca1 (0.97)0 (0.00)1 (0.97)0 (0.00) 
 3, 41 (0.97)1 (0.97)0 (0.00)0 (0.00) 
 Other1 (0.97)1 (0.97)0 (0.00)0 (0.00) 
Recurrence
 No63 (61.76)14 (13.73)26 (25.49)23 (22.55)0.1000
 Yes39 (38.24)5 (4.90)11 (10.78)23 (22.55) 
Grade
 G13 (2.91)1 (0.97)1 (0.971 (0.97) 
 G246 (44.66)10 (9.71)14 (13.59)22 (21.36)0.6015
 G354 (52.43)8 (7.77)23 (22.33)23 (22.33) 
Progression
No73 (72.28)17 (16.83)29 (28.71)27 (26.73)0.0570
Yes28 (27.72)2 (1.98)9 (8.91)17 (16.83) 
Survival status
 Alive84 (81.55)18 (17.48)36 (34.95)30 (29.13)0.0006
 Dead19 (18.45)1 (0.97)2 (1.94)16 (15.53) 
Duration of clinical follow-up (years) 4.165000005.007555563.874642860.1883